Overview
Novo Nordisk of Bagsværd, Denmark, discovers, develops, manufactures and markets pharmaceutical products through two segments, Diabetes and Obesity Care, and Rare Disease.[2] Forbes records sales of US$50.9bn, 20.8% above the prior-year figure, and profit of US$18.9bn, giving it the highest profit margin in this ranking at 37%.[2] The growth moved it from twelfth to tenth place. Its market value of US$206.9bn is less than a quarter of Eli Lilly’s, although both companies sell competing medicines for diabetes and obesity.[2] Forbes traces the company to 1923, when it was founded by Harald and Thorvald Pedersen, and counts 68,794 employees.[2]
Novo Nordisk strengths and limitations
Strengths
- Highest profit margin in the list
- Sales growth of 20.8%
- Leading position in insulin and GLP-1 drugs
Limitations
- Market value far below Lilly's
- Revenue concentrated in one therapy area
- Competition in obesity is increasing
Appears in
Novo Nordisk peers and competitors
Companies ranked in the same lists as Novo Nordisk.
Johnson & Johnson
Takeda Pharmaceutical
Daiichi Sankyo- Astellas Pharma
Viatris- Regeneron Pharmaceuticals
- CSL
Otsuka Holdings- Teva Pharmaceutical
Merck KGaA
Gilead Sciences- Amgen
Is this your company?
Update the description, logo, image and link through the submission form. Editors review every change.